Toroso Investments LLC Raises Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Toroso Investments LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 315.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 28,219 shares of the biopharmaceutical company’s stock after purchasing an additional 21,425 shares during the period. Toroso Investments LLC’s holdings in Gilead Sciences were worth $1,943,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of GILD. Albion Financial Group UT acquired a new stake in shares of Gilead Sciences in the 2nd quarter worth $27,000. Sawyer & Company Inc acquired a new stake in shares of Gilead Sciences in the second quarter valued at about $28,000. Meridian Wealth Partners LLC acquired a new stake in shares of Gilead Sciences in the first quarter valued at about $32,000. Elmwood Wealth Management Inc. acquired a new position in Gilead Sciences during the first quarter worth about $35,000. Finally, Samalin Investment Counsel LLC purchased a new stake in shares of Gilead Sciences during the second quarter worth about $58,000. 78.04% of the stock is currently owned by institutional investors.

NASDAQ GILD opened at $67.63 on Thursday. The company’s 50 day moving average is $70.59 and its 200-day moving average is $68.42. The firm has a market cap of $84.80 billion, a P/E ratio of 16.50, a price-to-earnings-growth ratio of 0.63 and a beta of 0.39. Gilead Sciences, Inc. has a 12-month low of $56.56 and a 12-month high of $73.34. The company has a quick ratio of 1.19, a current ratio of 1.36 and a debt-to-equity ratio of 1.42.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, July 29th. The biopharmaceutical company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.76 by $0.11. Gilead Sciences had a net margin of 19.38% and a return on equity of 55.94%. The company had revenue of $6.22 billion during the quarter, compared to analysts’ expectations of $6.15 billion. During the same quarter in the previous year, the company earned $1.11 earnings per share. Equities analysts expect that Gilead Sciences, Inc. will post 7.15 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 29th. Stockholders of record on Wednesday, September 15th were paid a $0.71 dividend. The ex-dividend date of this dividend was Tuesday, September 14th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 4.20%. Gilead Sciences’s dividend payout ratio (DPR) is 40.06%.

Several research firms recently issued reports on GILD. Oppenheimer began coverage on shares of Gilead Sciences in a report on Monday, June 28th. They issued a “buy” rating and a $100.00 price target on the stock. BMO Capital Markets upped their price objective on shares of Gilead Sciences from $67.00 to $72.00 and gave the company a “market perform” rating in a research note on Friday, July 30th. Royal Bank of Canada restated a “buy” rating and set a C$84.00 price target on shares of Gilead Sciences in a report on Monday, August 23rd. SVB Leerink raised their price target on shares of Gilead Sciences from $74.00 to $77.00 and gave the stock an “outperform” rating in a research report on Friday, July 30th. Finally, Morgan Stanley raised their price objective on shares of Gilead Sciences from $83.00 to $84.00 and gave the stock an “overweight” rating in a report on Tuesday. Eight research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $105.72.

In related news, CAO Diane E. Wilfong sold 13,610 shares of the company’s stock in a transaction on Tuesday, August 17th. The shares were sold at an average price of $72.50, for a total transaction of $986,725.00. Following the completion of the sale, the chief accounting officer now directly owns 30,179 shares in the company, valued at approximately $2,187,977.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.12% of the stock is currently owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Further Reading: What is the Stochastic Momentum Index (SMI)?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.